TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07318805: A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-08032562 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS

Sponsor: Pfizer · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 260 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$4,869,480

Rescue Site Savings

+$3,204,432

Unlock Full NCT07318805 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07318805 Rescue Dossier →